View Author
Orlent, H.
( H. Orlent)
patient hepatitis c treatment hepatitis ribavirin genotype response interferon therapy virological virological response rates genotypes 2 virological response study 48 weeks genotype 1 effect trial peg-ifn combination cirrhosis induction hepatology 24 weeks amantadine peginterferon-a il 28b polymorphism response rates ribavirin therapy group analysis cytopenia randomised hepatitis c virus interferon alfa -2b table genotype 1 patients month polymorphism virus efficacy randomized duration treatment duration infection result response rate peginterferon t r e hepatol peginterferon alfa -2a liver vrolijk virological response rate high-dose hepatitis c patients double-blind future randomised trial placebo-controlled placebo-controlled trial consensus peg-interferon author history characteristic count presence schedule level march monotherapy il 28b fibrosis unfavourable baseline characteristics hepatology 2012 vol 1200 mg /day reduction inclusion bias schalm sw
2 Most Recent Publications
|
IL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?
(Article)
Orlent, H. Knegt, R.J. de Janssen, H.L.A. |
2012-03-01
|
|
The treatment of hepatitis C: history, presence and future
(Article)
Vrolijk, J.M. Knegt, R.J. de Veldt, B.J. Orlent, H. Schalm, S.W. |
2004-01-01
|
